Please assess the completion status of the following clinical trial:

Trial Title: Clevidipine in the Treatment of Patients With Severe Hypertension (VELOCITY)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Systolic blood pressure \>180 mmHg and/or diastolic blood pressure \>115 mmHg assessed on two successive occasions, 15 minutes apart at baseline~* Written informed consent~Exclusion Criteria:~* SBP ≤180 mmHg and/or DBP ≤115 mmHg~* Expectation that the patient will not tolerate intravenous antihypertensive therapy for at least 18 hours~* Known or suspected aortic dissection~* Administration of an agent for treating hypertension within 2 hours of clevidipine administration~* Severe hypertension known to be precipitated by use of, or withdrawal from, alcohol or illicit drugs, or intentional overdose of illicit or prescription drugs~* Positive pregnancy test~* Intolerance to calcium channel blockers~* Allergy to soybean oil or egg lecithin~* Known liver failure or cirrhosis~* Participation in clinical research studies of other investigational drugs or devices within 30 days of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- clevidipine (Type: EXPERIMENTAL): A patient-specific blood pressure target range (TR) of ≥20 mm Hg and ≤40 mm Hg SBP was prespecified by the investigator. Once established, clevidipine (0.5 mg/mL in 20% lipid emulsion) intravenous infusion was initiated at 2.0 mg/h and maintained for the first 3 minutes. Clevidipine was up-titrated, as tolerated by the patient, by doubling the dose every 3 minutes until the prespecified systolic blood pressure (SBP) target range was achieved and could continue to be titrated up or down to maintain the desired long-term SBP reduction.

Based on this trial design, predict the completion outcome and termination type (if applicable).